Historically, the EGFR TKIs erlotinib and gefitinib showed clinical activity against the tumors exhibiting corresponding mutations and a similar activity was proved for the TKI crizotinib and ALK-rearranged cancers[1]. This evidence concerns the gene EGFR and cancer.